Serum levels of angiogenic factors in early breast cancer remain close to normal

被引：15

作者：

Duranyildiz, Derya ^{[1
]}

Camlica, Hakan ^{[1
]}

Soydinc, Hilal Oguz ^{[1
]}

Derin, Duygu ^{[1
]}

Yasasever, Vildan ^{[1
]}

机构：

[1] Istanbul Univ, Inst Oncol, TR-34390 Istanbul, Turkey

来源：

BREAST | 2009年 / 18卷 / 01期

关键词：

VEGF; Angiogenin; Tranforming growth factor-beta 1; Breast cancer; ENDOTHELIAL GROWTH-FACTOR; FACTOR-BETA; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; PLASMA-LEVELS; FACTOR VEGF; EXPRESSION; TGF-BETA(1); PROGRESSION; PROGNOSIS;

D O I：

10.1016/j.breast.2008.09.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The study which we performed was to determine serum concentrations of angiogenic factors including VEGF, angiogenin and TGF-beta 1 in early stage breast cancer patients. These parameters were measured by ELISA in sera of 90 patients with breast cancer and 75 healthy controls. The mean serum VEGF concentration in patients compared to controls was not significantly different (0.33 ng/mL vs 0.43 ng/mL, respectively; p = 0.156). Likewise, the insignificant change in mean values in patients vs controls was also observed for serum TGF-beta 1 (0.19 ng/mL vs 0.19 ng/mL, respectively; p = 0.215) and serum angiogenin (243.24 ng/mL vs 244.5 ng/mL, respectively; p = 0.976). Statistically significant correlation was found only between the tests, Such as VEGF and angiogenin in patients who were included in the study (p < 0.001). In conclusion, we couldn't find any diagnostic value between the early stage breast cancer and the three angiogenic parameters. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：26 / 29

页数：4

共 34 条

[1] Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative [J].

Bossuyt, PM ;

Reitsma, JB ;

Bruns, DE ;

Gatsonis, CA ;

Glasziou, PP ;

Irwig, LM ;

Lijmer, JG ;

Moher, D ;

Rennie, D ;

de Vet, HCW .

FAMILY PRACTICE, 2004, 21 (01) :4-10

[2]

Byrne GJ, 2007, ANTICANCER RES, V27, P3481

[3] Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival [J].

Campo, L ;

Turley, H ;

Han, C ;

Pezzella, F ;

Gatter, KC ;

Harris, AL ;

Fox, SB .

JOURNAL OF PATHOLOGY, 2005, 205 (05) :585-591

[4]

Cardillo MR, 2000, ANAL QUANT CYTOL, V22, P1

[5] Systemic effects of surgery:: quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-β) in patients with breast cancer who underwent limited or extended surgery [J].

Curigliano, G ;

Petit, JY ;

Bertolini, F ;

Colleoni, M ;

Peruzzotti, G ;

de Braud, F ;

Gandini, S ;

Giraldo, A ;

Martella, S ;

Orlando, L ;

Munzone, E ;

Pietri, E ;

Luini, A ;

Goldhirsch, A .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) :35-40

[6] Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments [J].

Dittadi, R ;

Meo, S ;

Fabris, F ;

Gasparini, G ;

Contri, D ;

Medici, M ;

Gion, M .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (02) :87-96

[7] Role of transforming growth factor beta in human cancer [J].

Elliott, RL ;

Blobe, GC .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :2078-2093

[8] The 2003 revised TNM staging system for breast cancer: Results of stage re-classification on survival and future comparisons among stage groups [J].

Escobar, Pedro F. ;

Patrick, Rebecca J. ;

Rybicki, Lisa A. ;

Weng, David E. ;

Crowe, Joseph P. .

ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (01) :143-147

[9]

Gasparini G, 2000, Oncologist, V5 Suppl 1, P37

[10] TGF-β in blood:: a complex problem [J].

Grainger, DJ ;

Mosedale, DE ;

Metcalfe, JC .

CYTOKINE & GROWTH FACTOR REVIEWS, 2000, 11 (1-2) :133-145

← 1 2 3 4 →